INVEX Therapeutics Ltd (IXC) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.171x

Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has a cash flow conversion efficiency ratio of -0.171x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-779.73K ≈ $-551.71K USD) by net assets (AU$4.55 Million ≈ $3.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

INVEX Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)

This chart illustrates how INVEX Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IXC total liabilities for a breakdown of total debt and financial obligations.

INVEX Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of INVEX Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Farlim Group (Malaysia) Bhd
KLSE:6041
-0.026x
DY6 Metals Ltd
AU:DY6
-0.086x
Castelbajac Co. Ltd
KQ:308100
-0.057x
Cell Impact AB
ST:CI
-0.104x
Mountain Province Diamonds Inc
TO:MPVD
0.020x
Advent Wireless Inc
V:AWI
0.030x
Edgewater Wireless Systems Inc
V:YFI
0.404x
Sumber Mas Konstruksi Tbk PT
JK:SMKM
-0.018x

Annual Cash Flow Conversion Efficiency for INVEX Therapeutics Ltd (2019–2025)

The table below shows the annual cash flow conversion efficiency of INVEX Therapeutics Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is INVEX Therapeutics Ltd worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$5.25 Million
≈ $3.71 Million
AU$-652.57K
≈ $-461.74K
-0.124x +71.05%
2024-06-30 AU$5.69 Million
≈ $4.02 Million
AU$-2.44 Million
≈ $-1.73 Million
-0.430x -32.80%
2023-06-30 AU$21.23 Million
≈ $15.02 Million
AU$-6.87 Million
≈ $-4.86 Million
-0.324x -172.89%
2022-06-30 AU$28.48 Million
≈ $20.15 Million
AU$-3.38 Million
≈ $-2.39 Million
-0.119x -126.62%
2021-06-30 AU$32.08 Million
≈ $22.70 Million
AU$-1.68 Million
≈ $-1.19 Million
-0.052x +20.38%
2020-06-30 AU$24.40 Million
≈ $17.27 Million
AU$-1.60 Million
≈ $-1.13 Million
-0.066x -226.59%
2019-06-30 AU$11.44 Million
≈ $8.09 Million
AU$-230.13K
≈ $-162.83K
-0.020x --

About INVEX Therapeutics Ltd

AU:IXC Australia Biotechnology
Market Cap
$6.91 Million
AU$9.77 Million AUD
Market Cap Rank
#27706 Global
#1458 in Australia
Share Price
AU$0.13
Change (1 day)
+0.00%
52-Week Range
AU$0.08 - AU$0.16
All Time High
AU$1.67
About

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more